Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial for advanced Gastric or Gastroesophageal junction cancer (Combination therapy) in South Korea

Trial Profile

Phase I/II trial for advanced Gastric or Gastroesophageal junction cancer (Combination therapy) in South Korea

Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Oct 2018 New trial record
    • 01 Oct 2018 According to LSK Biopharma media release, that the South Korean Ministry of Food and Drug Safety (MFDS) has approved a Phase I/IIa study protocol to investigate the combination of rivoceranib and paclitaxel.
    • 01 Oct 2018 According to LSK Biopharma media release, patient enrollment start in in October 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top